You are here: Home » Companies » News
Business Standard

CCI gives green signal to merger of Shasun Pharma with Strides

The combination would create a company with a turnover of Rs 2,500 cr, placing the combined entity among the top 15 listed drug makers

Press Trust of India  |  New Delhi 

Strides-Arcolab

Fair trade watchdog CCI has given its approval to the proposed merger of Chennai-based Shasun Pharmaceuticals with drug maker Strides Arcolab.

"The proposed combination is not likely to have any appreciable adverse effect on competition in India and therefore, the Commission hereby approves the proposed combination," the Competition Commission of India (CCI) said in an order dated March 4.

Under the proposed deal, Shasun will amalgamate with Strides in an all-stock transaction.

The combination of Strides and Shasun would create a company with a turnover of Rs 2,500 crore, placing the combined entity among the top 15 listed drug makers.

Shashun shareholders would receive 5 equity shares of Strides for every 16 shares held by them in Shasun.

Based on the exchange ratio, Shasun shareholders would own 26 per cent of the combined entity.

Strides, a Bangalore-based firm develops and manufactures IP-led niche pharmaceutical products. It has 8 manufacturing facilities presence in more than 75 countries.

Incorporated in 1976, Shasun is a global supplier of development and manufacturing services for intermediates, API and formulations to the pharmaceutical industry.

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Mon, March 23 2015. 19:57 IST
RECOMMENDED FOR YOU
.